Investigating how certain blood cell mutations contribute to heart disease.
Clonal hematopoiesis, inflammasomes and atherosclerosis
This study is looking at how certain changes in blood cells can lead to heart problems by causing inflammation, and it's for people who want to understand more about how these changes affect their heart health and what new treatments might help.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11049522 on NIH RePORTER |
What this research studies
This research focuses on clonal hematopoiesis, a condition where specific mutations in blood cells increase the risk of atherosclerotic cardiovascular disease (CVD). The study aims to understand how these mutations, particularly in genes like TET2 and JAK2, lead to inflammation and the development of atherosclerosis. By using mouse models and human cells, researchers will explore the role of inflammasomes, which are protein complexes that trigger inflammatory responses, in this process. The ultimate goal is to identify new therapeutic approaches to reduce inflammation and improve heart health in affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with clonal hematopoiesis, particularly those with mutations in the TET2 or JAK2 genes.
Not a fit: Patients without clonal hematopoiesis or those with other unrelated cardiovascular conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that reduce inflammation and lower the risk of heart disease for patients with specific blood cell mutations.
How similar studies have performed: Previous research has shown that targeting inflammatory pathways can be effective in treating cardiovascular diseases, suggesting potential success for this approach.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Tall, Alan Richard — Columbia University Health Sciences
- Study coordinator: Tall, Alan Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.